The Real Word Study of Albumin-binding Taxol for Lung Cancer Treatment

• Conditions: Lung Cancer

• Registration Number: NCT03802409
• Lead Sponsor: The First Affiliated Hospital of Anhui Medical University

Brief Summary

The investigators conduct the real world study to explore the efficacy and safety of Albumin-binding taxol in lung cancer .

Detailed Description

Not available

Study Timeline

• Status Verified: 2019-01
• Study First Submitted: 2019-01-10
• Study First Submitted QC: 2019-01-10
• Study First Posted: 2019-01-14
• Last Update Submitted: 2019-01-18
• Study Start: 2019-01-20
• Last Update Posted: 2019-01-22
• Primary Completion: 2020-01-01
• Study Completion: 2020-06-30

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

1. Male or female patients .
2. Confirmed by Histopathology or Cytology of Lung Cancer
3. Patients should be voluntary to the trial and provide with signed informed consent
4. The researchers believe patients can benefit from the study.

Exclusion Criteria

1. Patients with a known history of allergic reactions and/or hypersensitivity attributed to Albumin-binding taxol or its accessories
2. Pregnant or lactating women
3. Patients with Albumin-binding taxol contraindications
4. Patients of doctors considered unsuitable for the trial

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Progress free survival	1 year	Progress free survival is defined as the length of time from random assignment to disease progression or to death resulting from any cause other than the progress.

Secondary Outcome Measures

Name	Time	Method
Overall Survival	3 year	overall survival is defined as the length of time from random assignment to death or to last contact.
Objective tumor response rate	1 year	Objective tumor response rate is defined as the percentage of subjects having achieved confirmed Complete Response + Partial Response as best overall response according to radiological assessments
disease control rate	1 year	Investigators will assess treatment response according to Response Evaluation Criteria in Solid Tumors 1.1

Trial Locations

Locations (1)

First Affiliated Hospital of Anhui Medical University; 🇨🇳 Hefei, Anhui, China